
JOSEPH R. BERGER, MD

Ruth L. Works Professor and Chairman, Department of Neurology,
University of Kentucky College of Medicine, Lexington, KY

The clinical features of PML

■ ABSTRACT

The symptoms associated with progressive multifocal leukoencephalopathy (PML) reflect the location of pathologic brain lesions. These symptoms include visual deficits, cognitive impairment, and motor weakness; in patients with acquired immunodeficiency syndrome (AIDS), presenting signs can also include gait disturbance, dysarthria, dysphasia, and ocular palsy. Recently, PML has been observed in patients treated with biologic agents; natalizumab recipients currently represent the second largest group of patients with PML (behind patients with AIDS). Although brain biopsy is the most accurate and reliable method for diagnosing PML, it is rarely used today. Diagnosis is usually based on detection of JC virus in the cerebrospinal fluid by polymerase chain reaction, the clinical presentation, and demonstration of PML brain lesions on magnetic resonance imaging. With immune reconstitution, the prognosis of PML has improved markedly.

Progressive multifocal leukoencephalopathy (PML) was a rare disease until the era of human immunodeficiency virus (HIV) infection, when the number of cases of PML markedly increased. We are now entering a new era in which PML is being observed in patients treated with biologic agents for diseases not associated with development of PML.

This article reviews the epidemiology and symptoms that characterize PML, the identification of lesions on radiographic imaging that support the diagnosis, the value of laboratory studies and immunocytochemistry in the diagnosis, and clinical outcomes.

■ CHANGING EPIDEMIOLOGY OF PML

The presentation and epidemiology of PML have evolved over the last several decades. Prior to the acquired immunodeficiency syndrome (AIDS) era, nearly one-

half of patients with PML were affected by visual deficits. Among patients with AIDS-related PML, motor weakness is a feature for more than one-half, while cognitive impairment is the most common clinical presentation in natalizumab-related PML, affecting nearly one-half of patients (**Figure**).

The pre-AIDS era

Lesions of subcortical white matter characterize PML and the patient's clinical manifestations reflect their location. Brooks and Walker¹ reviewed 69 pathologically confirmed and 40 virologically and pathologically confirmed cases of PML in the era before AIDS, and categorized the neurologic signs and symptoms at onset and during disease progression; the clinical picture had three significant findings:

- Impaired vision: Defective vision, most commonly homonymous hemianopsia, was the most frequent presenting sign, present in 35% to 45% of cases. At the time of diagnosis, 6% to 8% of the patients were cortically blind because of bioccipital pathology.
- Motor weakness: Motor weakness was the initial sign in 25% to 33% of patients. At the time of diagnosis, hemiparesis or hemiplegia was present in nearly all patients.
- Changes in mentation: A change in mentation, including personality change, difficulty with memory, emotional lability, and frank dementia, was the presenting sign in approximately one-third of cases and eventually involved most patients.

AIDS-related PML

The epidemiology of PML changed with the AIDS pandemic. From 1958 to 1984, Brooks and Walker¹ identified 230 cases of PML; in the period from 1981 to 1994, Berger and colleagues² described 154 cases of AIDS-related PML that had been identified by the University of Miami Medical Center and the Broward County medical examiner's office. The frequency of PML from 1991 through 1994 was 12-fold greater than the frequency 10 years earlier, from 1981 through 1984. Among the patients with AIDS-related PML, the most common initial symptoms were weakness (42%), speech abnormalities (40%), cognitive abnormalities (36%), gait abnormalities (29%), sensory loss (19%), and visual impairment (19%), followed by seizures, diplopia, and

Dr. Berger reported that he has no financial relationships that pose a potential conflict of interest with this article.

This article was developed from an audio transcript of Dr. Berger's presentation at a roundtable convened at Cleveland Clinic on January 31, 2011. The transcript was edited by the *Cleveland Clinic Journal of Medicine* staff for clarity and conciseness, and was then reviewed, revised, and approved by Dr. Berger.
doi:10.3949/ccjm.78.s2.03

limb incoordination. The most common findings at the time of initial physical examination were weakness (54%), followed by gait abnormalities (20%), cognitive abnormalities (20%), dysarthria (24%), aphasia (19%), sensory loss (19%), visual impairment (17%), and oculomotor palsy (6%). For about 5% of patients with PML, it is the heralding manifestation of AIDS.

Although clinical features consistent with cerebral hemisphere lesions are most common, brainstem and cerebellar findings are also observed. Among these are ataxia, dysmetria, dysarthria, and oculomotor nerve palsies.²⁻⁴ Other signs and symptoms associated with PML include headache, vertigo, seizures, sensory deficits, parkinsonism,⁵ aphasia, and neglect syndromes.¹⁻⁴ In some cases, the coexistence of encephalitis with HIV infection could have accounted for some of the symptoms.

PML associated with monoclonal antibody therapy

Natalizumab is an alpha-4-beta-1 integrin inhibitor approved for the treatment of relapsing-remitting multiple sclerosis (MS); patients taking natalizumab represent the second largest group with PML (the largest group is patients with AIDS). Natalizumab-associated PML has some noteworthy features. The most common clinical presentations are cognitive disorders (48%), motor abnormalities (37%), language disturbances (31%), and visual defects (26%). Lesions are often monofocal rather than multifocal and the most common site of involvement is the frontal lobe.⁶ Among MS patients with natalizumab-associated PML, 30% to 40% have gadolinium-enhancing lesions on magnetic resonance imaging (MRI) at the time of diagnosis.

■ IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME

The immune reconstitution inflammatory syndrome (IRIS) is a paradoxical clinical deterioration that typically occurs in the face of immunologic recovery (Table).^{7,8} Although not unique to PML or opportunistic infections, it is frequently observed in the setting of HIV infection and natalizumab-associated PML, and it may be concurrent with the diagnosis of PML.^{6,9}

Among patients with HIV, predictors for the development of IRIS include antiretroviral naiveté, profoundly low CD4 lymphocyte counts (< 50 cells/mm³), a rapid decrease in HIV load, and the presence of active or subclinical opportunistic infections at the time of initiation of combined antiretroviral therapy. Tan and colleagues⁸ have reported the largest series to date. Of the 54 patients in their series, 36 developed PML and IRIS simultaneously, and 18 had worsening of preexisting PML. Although some investigators have recommended corticosteroid therapy for PML-IRIS, no controlled trials have been conducted and caution has been advised,




FIGURE. Although certain findings are considered classic in progressive multifocal leukoencephalopathy (PML) patients, the percentage of patients affected has shifted as the disorder has evolved from the pre-acquired immunodeficiency syndrome (AIDS) era to PML associated with biologic therapies such as natalizumab. Prior to the AIDS era, nearly one-half of patients with PML were affected by visual deficits. Among patients with AIDS-related PML, motor weakness is a feature for more than one-half, while cognitive impairment is the most common clinical presentation of natalizumab-related PML, affecting nearly one-half of patients.^{1,2,6,9}

particularly in patients without contrast enhancement on MRI or mass effect.

■ DIAGNOSTIC TESTING: NEUROIMAGING, CEREBROSPINAL FLUID ANALYSIS

Neuroimaging, including computed tomography (CT) and MRI, is a useful diagnostic tool for investigating a patient with PML. Cerebrospinal fluid (CSF) analysis for the presence of JC virus (JCV) may play a significant role, but it primarily serves to rule out other illnesses.

Computed tomography: lesion size may not reflect clinical status

On CT, demyelinating lesions appear as subcortical hypodensities, often with a propensity for parieto-occipital areas that are confined to the white matter at the junction interface of the gray-white junction of the cortex.⁹⁻¹¹ Lesions may be seen in the corpus callosum, thalamus, and basal ganglia,⁹ but changes in the size of lesions observed on CT do not necessarily reflect clinical progression.¹² Prior to the availability of highly active antiretroviral therapy (HAART) for the treatment of AIDS, mass effect was exceptionally rare.

TABLE
Features of PML-IRIS

- Paradoxical worsening of clinical or radiographic finding with recovery of the immune system
- New or increased neurologic deficits
- Increase in the number or size of lesions on neuroimaging
- Contrast enhancement of brain lesions
- Brain edema
- Concurrent with diagnosis of PML

IRIS = immune reconstitution inflammatory syndrome; PML = progressive multifocal leukoencephalopathy

However, the development of IRIS with PML, typically in AIDS patients following the use of HAART, may be associated with edema.¹³ Single-dose intravenous contrast and delayed, double-dose contrast CT scanning enhancement is observed in a minority of patients, typically fewer than 10%.⁸ This enhancement is generally faint and peripherally located.

Magnetic resonance imaging may show lesions before clinical disease

MRI is vastly more sensitive than CT in detecting the demyelinating lesions of PML.^{9,14} On rare occasions, MRI will clearly demonstrate pathology when CT is normal. In fact, MRI may show lesions in advance of clinically apparent disease.¹⁵ The characteristics of these lesions are hyperintensity on T2-weighted imaging, fluid-attenuated inversion recovery sequences, and hypointensity on T1-weighted image. Apparent diffusion coefficients (ADC) on MRI are typically normal to low in new lesions and at the advancing edge of lesions; the ADC was typically higher in the center of lesions.¹⁶

As observed on CT, approximately 10% of patients exhibit a faint rim of gadolinium enhancement.^{2,9} Enhancement is more common with PML-IRIS, and the distribution of lesions parallels what is seen pathologically. Enhancement PML lesions have altered signal characteristics compared with the surrounding white matter.^{9,17-19} In contrast, 15% of HIV-associated PML showed gadolinium enhancement on MRI at the time of diagnosis.^{6,9}

Cerebrospinal fluid analysis

With the exception of polymerase chain reaction (PCR) for JCV, the primary utility of lumbar puncture in the setting of possible PML is to exclude the presence of other illnesses, including treatable infections.

CSF findings in patients with PML are nonspecific, with most patients demonstrating a normal profile. A

mild lymphocytic pleocytosis, which is rarely (if ever) more than 25 leukocytes/mL, occurs in 15% of patients. Total protein level is mildly elevated in approximately 20% to 30% of patients.

The CSF examination in HIV-infected patients with PML may reflect changes associated with HIV: low-grade lymphocytic pleocytosis (< 20 cells/mm³), mildly elevated protein (< 65 mg/dL), and elevated immunoglobulin G and oligoclonal bands. These abnormalities should not be attributed to PML.

DIAGNOSIS

The most reliable and accurate method for the diagnosis of PML remains brain biopsy that demonstrates the characteristic triad of histopathologic findings (demyelination, bizarre astrocytes, and enlarged oligodendrocyte nuclei) coupled with evidence of JCV infection. With respect to the latter, in situ hybridization or immunocytochemistry can be employed. In situ DNA-DNA hybridization is a method of annealing JCV DNA to complementary strands either in paraffin-embedded tissue or in frozen sections from biopsy samples.

In immunocytochemistry, antibodies to both T antigen and the common polyomavirus capsid antigen are used to detect cells undergoing productive viral infection. Cells that are positive by in situ hybridization are in a stage of active viral replication. Cells positive by immunocytochemistry that are expressing viral capsid antigens are in a stage of viral transcription and translation (ie, undergoing productive infection). In addition to their utility in confirming a diagnosis of PML, these techniques have demonstrated the presence of JCV in perivascular locations and at sites distant from foci of demyelination. Alternatively, PCR may be used to demonstrate JCV in brain tissue.

In the absence of biopsy, which few deem necessary today, a widely employed approach to diagnosis requires the demonstration of:

- JCV in the CSF by PCR
- Compatible clinical presentation
- An MRI finding consistent with PML
- No other alternative diagnosis.

With an ultrasensitive PCR technique, sensitivities should approach or may exceed 95%, but PCR sensitivity remains at 75% in some laboratories. Because the viral copy numbers in the CSF may be low, particularly in a patient treated with a monoclonal antibody such as natalizumab, the CSF PCR may be falsely negative.

If clinical suspicion of the disease remains high in the face of an initially negative CSF JCV, the CSF analysis should be repeated. CSF analysis for JCV is approximately 99% specific, but recent studies demonstrating low copy numbers of JCV in the CSF of patients with MS have raised concerns about potential pitfalls of this assay.²⁰

■ PROGNOSIS

Until recently, PML was regarded as virtually universally fatal. The mean survival in the pre-AIDS era was approximately 6 months, and mortality was 80% within 9 months of disease onset. Rarely, patients had long survivals that ranged from 5 years to 19 years.

In the early years of the AIDS era, survival with PML did not appear to differ significantly from that observed in the pre-AIDS years. In the largest study of HIV-associated PML in the era prior to HAART, the median survival was 183 days.² However, the majority of individuals were dead within 3 months of diagnosis. Only 8% to 10% of patients survived longer than 12 months, which has been regarded as “prolonged survival.” This long survival skewed the mean and median survival rates in this population.

Several factors have since been identified that correlate with prolonged survival in HIV-associated PML, including PML as the heralding manifestation of HIV, CD4 counts exceeding 300 cells per mm³, contrast enhancement of the lesions on radiographic imaging, low copy number or decreasing JCV titers in CSF^{21–24} and the presence of JCV-specific cytotoxic T cells.²⁵ A better prognosis has also been postulated for higher CSF levels of macrophage chemoattractant protein-1²⁶ and PML associated with JCV VP1 loop-specific polymorphisms.²⁷

Prognosis of HIV-associated PML improves with immune system restoration

In the era of HAART, not only has the incidence of HIV-associated PML declined, but the prognosis of affected patients has improved as well. This development highlights the importance of restoration of the immune system in both disease prevention and survival. Some estimate that as many as 50% of HAART-treated patients with PML exhibit prolonged survival. In one study of 25 patients, the median survival was more than 46 weeks.²⁸

Nonetheless, PML continues to have the worst prognosis of any AIDS-related cerebral disorder, with those having advanced immunosuppression being most susceptible to the disorder. For AIDS patients with PML, those who were HAART-naïve at the time of diagnosis appear to have better survival than treatment-experienced patients.²⁹ Survival also correlates with reduced JCV load in the CSF³⁰ and improved CD4 lymphocyte counts (CD4 counts > 100 cells/mm³).³¹

Prognosis of natalizumab-associated PML is different

The prognosis of natalizumab-associated PML differs from that of HIV-associated PML. In a series of 35 patients, 25 (71%) patients were alive on average 6 months after diagnosis.³² Prognosis was worse with a longer time to diagnosis and the presence of widespread disease.

Most deaths in patients taking natalizumab who developed PML have occurred during IRIS. Steroid treatment of IRIS appears to improve prognosis,⁸ but no scientifically rigorous study has been undertaken to demonstrate this recommendation.⁷ Among the survivors, neurologic deficit was mild in one-third, moderate in one-third, and severe in one-third of patients.

■ CONCLUSION: DISPELLING SOME MYTHS

Several assumptions about PML are not necessarily true. For example, although PML implies the presence of multifocal lesions as a characteristic of the disease, the lesions may be monofocal, especially with natalizumab-associated PML. The lesions of PML may show early gadolinium enhancement on neuroimaging. Although lesions typically are seen in subcortical white matter, cortical involvement also may be observed. Cerebellar granular cell degeneration may occur in association with PML or in isolation. Disease progression and death are not inevitable, even in the absence of treatment. The most important determinant for survival is restoration of the immune system.

■ DISCUSSION

Dr. Calabrese: Why are sensory deficits so common?

Dr. Berger: We don't know. Because we see involvement in the parietal lobe, we would anticipate observing sensory deficits. I think that a lot of sensation occurs deep in the thalamic area, which is not often involved in PML. Also, we often don't test for some of the deficits that may occur.

Dr. Rudick: Do you know of any cases of natalizumab-associated PML detected as an incidental finding on MRI, making a case for screening MRI in patients without clinical symptoms?

Dr. Berger: There have been a handful of cases, including one of the seminal cases of natalizumab-associated PML, in which MRI abnormalities were observed in advance of clinically recognized symptomatology.

Dr. Calabrese: The correlate question is, if a patient with a risk factor—be it HIV or treatment with a biologic agent—has a common neurocognitive sign or perhaps some subtle motor findings, does a normal MRI have 100% negative predictive value?

Dr. Berger: I have yet to see somebody with PML who has a normal MRI.

Dr. Simpson: What you may see are lesions that are not typical MRI lesions of white matter hypointensity. In some cases, as Dr. Berger mentioned in his summary, we'll see cerebellar degeneration—atrophy—but not necessarily white matter lesions.

■ REFERENCES

1. Brooks BR, Walker DL. Progressive multifocal leukoencephalopathy. *Neurol Clin* 1984; 2:299–313.
2. Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. *J Neurovirol* 1998; 4:59–68.
3. Parr J, Horoupian DS, Winkelman AC. Cerebellar form of progressive multifocal leukoencephalopathy (PML). *Can J Neurol Sci* 1979; 6:123–128.
4. Jones HR Jr, Hedley-Whyte ET, Freidberg SR, Kelleher JE Jr, Krolikowski J. Primary cerebellopontine progressive multifocal leukoencephalopathy diagnosed premortem by cerebellar biopsy. *Ann Neurol* 1982; 11:199–202.
5. O’Riordan S, McGuigan C, Farrell M, Hutchinson M. Progressive multifocal leukoencephalopathy presenting with parkinsonism. *J Neurol* 2003; 250:1379–1381.
6. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. *Lancet Neurol* 2010; 9:438–446.
7. Berger JR. Steroids for PML-IRIS. A double-edged sword? *Neurology* 2009; 72:1454–1455.
8. Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. *Neurology* 2009; 72:1458–1464.
9. Whiteman ML, Post MJ, Berger JR, Tate LG, Bell MD, Limonte LP. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. *Radiology* 1993; 187:233–240.
10. Conomy JP, Weinstein MA, Agamanolis D, Holt WS. Computed tomography in progressive multifocal leukoencephalopathy. *AJR Am J Roentgenol* 1976; 127:663–665.
11. Huckman MS. Computed tomography in the diagnosis of degenerative brain disease. *Radiol Clin North Am* 1982; 20:169–183.
12. Krupp LB, Lipton RB, Swerdlow ML, Leeds NE, Llena J. Progressive multifocal leukoencephalopathy: clinical and radiographic features. *Ann Neurol* 1985; 17:344–349.
13. Rushing EJ, Liappis A, Smirniotopoulos JD, et al. Immune reconstitution inflammatory syndrome of the brain: case illustrations of a challenging entity. *J Neuropathol Exp Neurol* 2008; 67: 819–827.
14. Post MJ, Sheldon JJ, Hensley GT, et al. Central nervous system disease in acquired immunodeficiency syndrome: prospective correlation using CT, MR imaging, and pathologic studies. *Radiology* 1986; 158:141–148.
15. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. *N Engl J Med* 2005; 353:375–381.
16. Bergui M, Bradac GB, Oguz KK, et al. Progressive multifocal leukoencephalopathy: diffusion-weighted imaging and pathological correlations. *Neuroradiology* 2004; 46:22–25.
17. Guilleux MH, Steiner RE, Young IR. MR imaging in progressive multifocal leukoencephalopathy. *AJNR Am J Neuroradiol* 1986; 7:1033–1035.
18. Levy JD, Cottingham KL, Campbell RJ, et al. Progressive multifocal leukoencephalopathy and magnetic resonance imaging. *Ann Neurol* 1986; 19:399–401.
19. Mark AS, Atlas SW. Progressive multifocal leukoencephalopathy in patients with AIDS: appearance on MR images. *Radiology* 1989; 173:517–520.
20. Iacobaeus E, Ryschkewitsch C, Gravell M, et al. Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA. *Mult Scler* 2009; 15:28–35.
21. Berger JR, Levy RM, Flomenhoft D, Dobbs M. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. *Ann Neurol* 1998; 44:341–349.
22. Taoufik Y, Gasnault J, Karaterki A, et al. Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. *J Infect Dis* 1998; 178:1816–1820.
23. Yiannoutsos CT, Major EO, Curfman B, et al. Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy. *Ann Neurol* 1999; 45:816–821.
24. Bossolasco S, Calori G, Moretti F, et al. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. *Clin Infect Dis* 2005; 40:738–744.
25. Du Pasquier RA, Clark KW, Smith PS, et al. JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy. *J Neurovirol* 2001; 7:318–322.
26. Marzocchetti A, Cingolani A, Giambenedetto SD, et al. Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. *J Neurovirol* 2005; 11:219–224.
27. Delbue S, Branchetti E, Bertolacci S, et al. JC virus VP1 loop-specific polymorphisms are associated with favorable prognosis for progressive multifocal leukoencephalopathy. *J Neurovirol* 2009; 15:51–56.
28. Clifford DB, Yiannoutsos C, Glicksman M, et al. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. *Neurology* 1999; 52:623–625.
29. Wyen C, Hoffmann C, Schmeisser N, et al. Progressive multifocal leukoencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death. *J Acquir Immune Defic Syndr* 2004; 37:1263–1268.
30. De Luca A, Giancola ML, Ammassari A, et al. The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. *J Infect Dis* 2000; 182:1077–1083.
31. Berenguer J, Miralles P, Arrizabalaga J, et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. *Clin Infect Dis* 2003; 36:1047–1052.
32. Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab associated progressive multifocal leukoencephalopathy. *Neurology* 2011; 76:1697–1704.

Correspondence: Joseph R. Berger, MD, Department of Neurology, University of Kentucky Medical Center, KY Clinic (Wing D) – L445, Lexington, KY 40536-0284; jrbneuro@email.uky.edu